Trial Profile

A Phase Ib/II clinical study of HLX701 in combination with cetuximab and chemotherapy for the treatment of patients with advanced RAS/BRAF wild-type colorectal cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Feb 2026 New trial record
20 Jan 2026 According to a Henlius Biopharmaceuticals media release, company has received approval from the National Medical Products Administration (NMPA) to initiate an 1b/2 clinical trial in combination with cetuximab and chemotherapy, for the treatment of patients with advanced RAS/BRAF wild-type colorectal cancer.
20 Jan 2026 According to a Henlius Biopharmaceuticals media release, the company has received approval by the National Medical Products Administration (NMPA) to conduct a Phase Ib/II clinical study in combination with cetuximab and chemotherapy for the treatment of patients with advanced RAS/BRAF wild-type colorectal cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com